Lupin launches Tobramycin Inhalation Solution USP in the US
In a significant development, Lupin launched its generic Tobramycin Inhalation Solution USP in the US markets on Wednesday.
Lupin's Tobramycin Inhalation Solution USP, 300 mg/5 ml is the generic equivalent of Novartis Pharmaceuticals Corporation's Tobis 300 mg/5 ml. It is used for the management of cystic fibrosis patients with P. aeruginosa and has an annual sales of around USD 99 million in the US.
In the past one month, the stock has gained over 13 per cent on the bourses. In Wednesday’s trade, the stock hit an intraday high of Rs. 880.80 per share and an intraday low of Rs. 861 per share on BSE. The stock had touched its 52-week high of Rs. 1,194 per share on June 15, 2017 and its 52-week low of Rs. 723.55 per share on May 15, 2018 on BSE, respectively.
The stock ended at at Rs. 869.60 per share, up by 1.79 per cent on BSE. Meanwhile, Indian benchmark indices S&P BSE Sensex ended at 35,739.16 level, up by 0.13 per cent and NSE Nifty50 closed at 10,856.70 level, up by 0.13 per cent.